Compare MSI & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSI | RLAY |
|---|---|---|
| Founded | 1928 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | MSI | RLAY |
|---|---|---|
| Price | $383.76 | $8.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $491.00 | $16.00 |
| AVG Volume (30 Days) | 1.5M | ★ 2.2M |
| Earning Date | 02-12-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | ★ 36.31 | N/A |
| EPS | ★ 12.46 | N/A |
| Revenue | ★ $11,313,000,000.00 | $8,355,000.00 |
| Revenue This Year | $8.75 | $20.47 |
| Revenue Next Year | $8.25 | N/A |
| P/E Ratio | $30.81 | ★ N/A |
| Revenue Growth | ★ 6.18 | N/A |
| 52 Week Low | $359.36 | $1.78 |
| 52 Week High | $492.22 | $9.04 |
| Indicator | MSI | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 56.87 | 60.20 |
| Support Level | $375.10 | $8.25 |
| Resistance Level | $380.10 | $8.76 |
| Average True Range (ATR) | 6.33 | 0.45 |
| MACD | 3.02 | -0.03 |
| Stochastic Oscillator | 92.54 | 61.41 |
Motorola Solutions is a leading provider of communications and analytics, primarily serving public safety departments as well as schools, hospitals, and businesses. The bulk of the firm's revenue comes from sales of land mobile radios and radio network infrastructure, but the firm also sells surveillance equipment, dispatch software, and other networking capabilities. Most of Motorola's revenue comes from government agencies, while roughly 25% comes from schools and private businesses. Motorola has customers in over 100 countries and in every state in the United States.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).